{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:01:41Z","timestamp":1770822101333,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ejca.2003.10.025","type":"journal-article","created":{"date-parts":[[2003,12,19]],"date-time":"2003-12-19T10:57:50Z","timestamp":1071831470000},"page":"963-970","source":"Crossref","is-referenced-by-count":58,"title":["Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas"],"prefix":"10.1016","volume":"40","author":[{"given":"J.K","family":"Anninga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J","family":"van de Vijver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M","family":"Cleton-Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.M.P","family":"Kristel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.M","family":"Taminiau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Nooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M","family":"Egeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.W","family":"Hogendoorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2003.10.025_BIB1","series-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone","first-page":"264","article-title":"Conventional osteosarcoma","author":"Raymond","year":"2002"},{"key":"10.1016\/j.ejca.2003.10.025_BIB2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1994.12.2.423","article-title":"Prognostic factors in osteosarcoma","volume":"12","author":"Davis","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.20.3.776","article-title":"Prognostic factors in high-grade osteosarcoma of the extremities or trunk","volume":"20","author":"Bielack","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0959-8049(02)00037-0","article-title":"Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup","volume":"38","author":"Hauben","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5","article-title":"ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma","volume":"77","author":"Onda","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB6","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","article-title":"Expression of HER2\/erbB-2 correlates with survival in osteosarcoma","volume":"17","author":"Gorlick","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB7","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/cncr.10360","article-title":"ErbB2 expression is correlated with increased survival of patients with osteosarcoma","volume":"94","author":"Akatsuka","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00043426-200301000-00007","article-title":"Her-2\/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification","volume":"25","author":"Zhou","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1126\/science.2999974","article-title":"Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene","volume":"230","author":"Coussens","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ejca.2003.10.025_BIB10","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The product of the human c-erbB-2 gene","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ejca.2003.10.025_BIB11","first-page":"165","article-title":"The biology of erbB-2\/neu\/HER-2 and its role in cancer","volume":"1198","author":"Hynes","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejca.2003.10.025_BIB12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1126\/science.2885917","article-title":"erbB-2 is a potent oncogene when overexpressed in NIH\/3T3 cells","volume":"237","author":"Di Fiore","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejca.2003.10.025_BIB13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejca.2003.10.025_BIB14","first-page":"1189","article-title":"Oncogenic potential of erbB-2 in human mammary epithelial cells","volume":"6","author":"Pierce","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2003.10.025_BIB15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0092-8674(85)80050-7","article-title":"Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies","volume":"41","author":"Drebin","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2003.10.025_BIB16","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/sj.onc.1202526","article-title":"Inhibitory effects of combinations of HER-2\/neu antibody and chemotherapeutic agents used for treatment of human breast cancers","volume":"18","author":"Pegram","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2003.10.025_BIB17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/modpathol.3880474","article-title":"Clinicopathologic analysis of HER-2\/neu immunoexpression among various histologic subtypes and grades of osteosarcoma","volume":"14","author":"Kilpatrick","year":"2001","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000058533","article-title":"Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma","volume":"60","author":"Akatsuka","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2003.10.025_BIB19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V","article-title":"Amplification of the HER-2\/neu oncogene is uncommon in pediatric osteosarcomas","volume":"92","author":"Maitra","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB20","first-page":"788","article-title":"Absence of HER2\/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma","volume":"8","author":"Thomas","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.025_BIB21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","article-title":"Randomised trial of two regimens of chemotherapy in operable osteosarcoma","volume":"350","author":"Souhami","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2003.10.025_BIB22","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1200\/JCO.1999.17.10.3260","article-title":"Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone","volume":"17","author":"Bramwell","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB23","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.1994.12.9.1842","article-title":"Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma","volume":"12","author":"Ornadel","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.1992.10.10.1579","article-title":"A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults","volume":"10","author":"Bramwell","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0215(20010701)93:1<114::AID-IJC1309>3.0.CO;2-J","article-title":"Determining MDR1\/P-glycoprotein expression in breast cancer","volume":"93","author":"Faneyte","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/j.1460-2075.1987.tb04797.x","article-title":"Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms","volume":"6","author":"Kraus","year":"1987","journal-title":"EMBO J."},{"key":"10.1016\/j.ejca.2003.10.025_BIB27","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1128\/MCB.7.5.2019","article-title":"Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene","volume":"7","author":"Van de Vijver","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB28","first-page":"4185","article-title":"Heterogeneous expression of erbB-2 messenger RNA in human breast cancer","volume":"49","author":"King","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.025_BIB29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bjc.1990.9","article-title":"C-erbB2 mRNA expression in human breast tumours","volume":"61","author":"Parkes","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB30","first-page":"63","article-title":"Detection and quantitation of HER-2\/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization","volume":"13","author":"Pauletti","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2003.10.025_BIB31","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<273::AID-IJC13>3.0.CO;2-7","article-title":"c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples","volume":"84","author":"Farabegoli","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/1097-0215(20010720)95:4<266::AID-IJC1045>3.0.CO;2-E","article-title":"c-erbB-2 (HER-2\/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients","volume":"95","author":"Riou","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2003.10.025_BIB33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(00)00403-2","article-title":"Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2)","volume":"37","author":"Van de Vijver","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejca.2003.10.025_BIB34","first-page":"2771","article-title":"Sensitivity of HER-2\/neu antibodies in archival tissue samples","volume":"54","author":"Press","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejca.2003.10.025_BIB35","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer","volume":"18","author":"Pauletti","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB36","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1136\/jcp.47.9.816","article-title":"C-erbB-2 immunostaining","volume":"47","author":"Kay","year":"1994","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB37","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/modpathol.3880440","article-title":"HER-2\/neu in breast cancer","volume":"14","author":"Thomson","year":"2001","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.MP.0000052102.90815.82","article-title":"Current Perspectives on HER2 Testing","volume":"16","author":"Bilous","year":"2003","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ejca.2003.10.025_BIB39","first-page":"311","article-title":"C-erbB-2 mRNA in breast cancer specimens that exhibit membrane or cytoplasmic immunoreactivity for c-erbB-2","volume":"11","author":"Taylor","year":"1999","journal-title":"Oncol Res."},{"key":"10.1016\/j.ejca.2003.10.025_BIB40","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","article-title":"Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications","volume":"45","author":"Bieche","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejca.2003.10.025_BIB41","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1073\/pnas.89.12.5321","article-title":"ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization","volume":"89","author":"Kallioniemi","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejca.2003.10.025_BIB42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/gcc.10132","article-title":"Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas","volume":"36","author":"Bayani","year":"2003","journal-title":"Genes Chromosomes Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903009638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804903009638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T06:51:09Z","timestamp":1585378269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804903009638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0959804903009638"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2003.10.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}